Page last updated: 2024-12-07

n,n'-diallyltartardiamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

N,N'-diallyltartardiamide: cross linking reagent; RN given refers to (R-(R*,R*))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID98486
CHEBI ID184080
SCHEMBL ID107767
MeSH IDM0054445

Synonyms (38)

Synonym
butanediamide, 2,3-dihydroxy-n,n'-di-2-propenyl-
CBDIVE_003321
n,n'-diallyl-2,3-dihydroxy-butanediamide
n~1~,n~4~-diallyl-2,3-dihydroxysuccinamide
nsc145415
nsc-145415
28843-34-7
n,n'-diallyltartardiamide
D-0950
datd
n,n'-diallyltartramide
inchi=1/c10h16n2o4/c1-3-5-11-9(15)7(13)8(14)10(16)12-6-4-2/h3-4,7-8,13-14h,1-2,5-6h2,(h,11,15)(h,12,16)
2,3-dihydroxy-n,n'-di(prop-2-enyl)butanediamide
zrkleahgbndkhm-uhfffaoysa-
D1539
(+)-n,n'-diallyl-l-tartramide
(+)-n,n'-diallyl-l-tartardiamide
2,3-dihydroxy-n,n'-bis(prop-2-enyl)butanediamide
CHEBI:184080
n,n'-diallyl-2,3-dihydroxysuccinamide
(2r,3r)-2,3-dihydroxy-n,n'-bis(prop-2-enyl)butanediamide
AKOS004903293
ai3-62352
nsc 145415
einecs 249-267-7
FT-0629377
FT-0629378
FT-0629435
SCHEMBL107767
n,n'-diallyl-l-(+)-tartardiamide
butanediamide, 2,3-dihydroxy-n,n'-di-2-propenyl-, [r-(r*,r*)]-
(+)-n,n'-diallyltartardiamide
ZRKLEAHGBNDKHM-UHFFFAOYSA-N
n,n'-diallyl tartardiamide
butanediamide,2,3-dihydroxy-n1,n4-di-2-propen-1-yl-
n1,n4-diallyl-2,3-dihydroxysuccinamide
2,3-dihydroxy-n~1~,n~4~-di(prop-2-en-1-yl)butanediamide
DTXSID50866693
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
fatty amideA monocarboxylic acid amide derived from a fatty acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (54.55)18.7374
1990's3 (27.27)18.2507
2000's2 (18.18)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (9.09%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]